Research
Categories
Impact of DAA scale-up on HCV RNA prevalence in a community of PWID in Imphal, India. A sero-epidemiology and modelling study.
Principal Investigators
:
Dr Amrose Pradeep, Dr R Balakrishnan
Funding Agency
:
Gilead India Private Limited
FCRA
Ongoing
Clinical
Objectives:
- Primary objective: To evaluate the impact of integrating HCV treatment with existing HIV and harm reduction services on chronic HCV prevalence and HCV incidence in the community.
- Secondary objectives: To measure incidence and correlates of HCV reinfection among PWID who achieve SVR
- To assess whether 2030 elimination targets can be achieved in PWID through epidemic modelling
